Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: In vitro and in vivo studies

Leukemia

Volumn 28, Issue 4, 2014, Pages 904-916

  Frassanito, M A ^a   Rao, L ^b   Moschetta, M ^b   Ria, R ^b   Di Marzo, L ^b   De Luisi, A ^b   Racanelli, V ^b   Catacchio, I ^b   Berardi, S ^b   Basile, A ^b   Menu, E ^c   Ruggieri, S ^b   Nico, B ^b   Ribatti, D ^b,d   Fumarulo, R ^a   Dammacco, F ^b   Vanderkerken, K ^c   Vacca, A ^b  

^a Department of Biomedical Sciences and Human Oncology   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

cancer associated fibroblasts; multiple myeloma; tumor microenvironment

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; INTEGRIN; INTERLEUKIN 6; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CELL ADHESION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR GROWTH; TUMOR XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLASTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MULTIPLE MYELOMA; PHENOTYPE;

EID: 84898466234     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.254     Document Type: Article

References (50)

1. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54-59. (Pubitemid 32119278)
2. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-815. (Pubitemid 47040863)
3. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-1601. (Pubitemid 44285243)
4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
5. Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010; 21: 33-39.
6. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumor progression. Semin Cell Dev Biol 2010; 21: 19-25.
7. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 Secretion. Cell 2005; 121: 335-348. (Pubitemid 40692295)
8. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010; 17: 135-147.
9. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238.
10. Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 2007; 6: 618-619. (Pubitemid 47328338)
11. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006; 5: 1640-1646.
12. Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009; 8: 1461-1462.
13. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblasts: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816. (Pubitemid 47339255)
14. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP et al. Carcinoma-associated fibroblasts-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-4339.
15. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004; 64: 8492-8495. (Pubitemid 39552057)
16. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007; 67: 10123-10128. (Pubitemid 350070783)
17. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
18. Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 2003; 14: 538-546. (Pubitemid 37298041)
19. Tschumperlin DJ, Dai G, Maly IV, Kikuchi T, Laiho LH, McVittie AK et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature 2004; 429: 83-86. (Pubitemid 38620555)
20. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 2009; 28: 113-127.
21. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-20014.
22. Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M, Vacca A. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res 2011; 1: 76-89.
23. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199. (Pubitemid 43148652)
24. Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A et al. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol 2013; 229: 87-98.
25. Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R et al. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene 2012; 31: 2258-2269.
26. Santos AM, Jung J, Aziz N, Kissil JL, Purè E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119: 3613-3625.
27. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002; 46: 3349-3360. (Pubitemid 35453547)
28. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012; 120: 20-30.
29. Ria R, Piccoli C, Cirulli T, Falzetti F, Mangialardi G, Guidolin D et al. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin Cancer Res 2008; 14: 1678-1685. (Pubitemid 351469451)
30. Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 2012; 30: 266-279.
31. Mö ller C, Strömberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203-210.
32. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38: 71-81. (Pubitemid 30224324)
33. Saito RA, Micke P, Paulsson J, Augsten M, Peña C, Jö nsson P et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010; 70: 2644-2654.
34. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012; 122: 3603-3617.
35. Ö stman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009; 19: 67-73.
36. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996; 87: 1928-1938. (Pubitemid 26068909)
37. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004; 10: 7540-7546. (Pubitemid 39557515)
38. Markwald RR, Fitzharris TP, Smith WN. Sturctural analysis of endocardial cytodifferentiation. Dev Biol 1975; 42: 160-180.
39. van Meeteren LA, ten Dijke P. Regulation of endothelial cell plasticity by TGF-b. Cell Tissue Res 2012; 347: 177-186.
40. Moonen JR, Krenning G, Brinker MG, Koerts JA, van Luyn MJ, Harmsen MC. Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny. Cardiovasc Res 2010; 86: 506-515.
41. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992.
42. Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007; 110: 4373-4384. (Pubitemid 351377804)
43. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 27-42. (Pubitemid 27147744)
44. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007; 21: 44-52. (Pubitemid 44921833)
45. Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic mielogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001; 15: 1232-1239. (Pubitemid 32776447)
46. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002; 2: 37-43. (Pubitemid 34627377)
47. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-1182. (Pubitemid 36722250)
48. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F et al. alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001; 29: 993-1003. (Pubitemid 32725797)
49. van Riet I, de Greef C, del Favero H, Demanet C, Van Camp B. Production of fibronectin and adherence to fibronectin by human myeloma cell lines. Br J Haematol 1994; 87: 258-265. (Pubitemid 24204725)
50. Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 2009; 57: 239-247.